Immunotherapy after bladder cancer surgery may reduce recurrence, study shows
New research found that using nivolumab reduced bladder cancer recurrence after surgery compared to patients who received placebo
2021-06-03
(Press-News.org) NEW YORK CITY, June 2, 2021 -- New research from Memorial Sloan Kettering Cancer Center (MSK) medical oncologist Dean Bajorin, MD, and colleagues found that patients who received nivolumab (Opdivo®) after bladder cancer surgery reduced their overall risk for high-grade bladder cancer recurrence. This research was published in the New England Journal of Medicine.
In this phase III randomized study, Dr. Bajorin and a team of investigators evaluated 709 patients who were at high risk for recurrence of urothelial cancer after removal of their bladder, ureter, or kidney for high-grade cancer. To evaluate for benefit, patients were randomized to receive either nivolumab or a placebo every two weeks for one year. Patients and physicians were blinded to the treatment. Both safety and quality of life were evaluated.
Dr. Bajorin and investigators found that in high-risk patients, nivolumab reduced recurrence after surgery compared to patients who received the placebo. The current standard of care following surgery that removes the bladder or kidney and ureter has been observation without adjuvant therapy -- even in patients at high risk of recurrence and death. This is because no chemotherapy or immunotherapy has previously been shown to be of benefit. Participants who received nivolumab had disease-free survival of 21 months compared with 10.9 months in people receiving the placebo.
"We are very encouraged by the data and the results of the study," said Dr. Bajorin, first and corresponding author of the study. "Despite available therapies for advanced metastatic bladder cancer, new options are needed to improve long-term disease control and patient survival. These findings have the potential to change the standard of care for bladder cancer."
Urothelial cancers are tumors that start in the lining of the urine-collecting system that transports urine from the kidneys to the outside of our bodies. These cancers are often referred to as "bladder cancer" because most of them start in the bladder.
Dr. Bajorin and colleagues concluded that the survival data is not yet mature and will need additional research and follow-up. The primary endpoints of disease-free survival in the study population and disease free-survival in the subset of patients with PD-L1-positive tumors were met, and these findings are highly statistically significant and clinically relevant for a population of patients with a clear unmet medical need.
"The trial demonstrates that novel therapies can be identified as having patient benefit when the studies are conducted in a very rigorous fashion. We are hoping this treatment will get approval for all patients at high risk of recurrence after the US Food and Drug Administration has done a detailed review of all the data," said Dr. Bajorin.
Making Pioneering Advances for Bladder Cancer Patients
Cancer immunotherapy was born at MSK a little over a century ago. Since then, physician-scientists across MSK have led the effort to develop immune-based treatments for different types of cancer. MSK has been at the epicenter of discoveries in the field, and the institution's work is bringing exciting new treatment options to people around the world. MSK physicians have extensive experience using immunotherapy to treat people with melanoma, kidney cancer, lung cancer, and other cancers as well as handling immune-related side effects.
Without treatment, bladder cancer can be an aggressive disease. In 2021, it is estimated that there will be nearly 17,000 deaths due to bladder cancer in the United States -- and numbers are expected to rise significantly in the next decade.
"As physicians, we consistently strive to provide our patients with the most effective therapies and give those with advanced disease more options," said Dr. Bajorin.
INFORMATION:
This trial was sponsored by Bristol Myers Squibb, Checkmate 274.
About Memorial Sloan Kettering (MSK):
As the world's oldest and largest private cancer center, Memorial Sloan Kettering has devoted more than 135 years to exceptional patient care, influential educational programs, and innovative research to discover more effective strategies to prevent, control and, ultimately, cure cancer. MSK is home to more than 20,000 physicians, scientists, nurses, and staff united by a relentless dedication to conquering cancer. Today, we are one of 51 National Cancer Institute-designated Comprehensive Cancer Centers, with state-of-the-art science and technology supporting groundbreaking clinical studies, personalized treatment, and compassionate care for our patients. We also train the next generation of clinical and scientific leaders in oncology through our continually evolving educational programs, here and around the world. Year after year, we are ranked among the top two cancer hospitals in the country, consistently recognized for our expertise in adult and pediatric oncology specialties. http://www.mskcc.org.
ELSE PRESS RELEASES FROM THIS DATE:
2021-06-03
A complex zone of folding and faulting that links two faults underneath downtown Salt Lake City could deform the ground during a large earthquake, according to a new study.
The findings, published in the open-access journal The Seismic Record, suggest that earthquakes magnitude 5.0 and larger could cause ground displacement and liquefaction in Salt Lake City that increase the risk of earthquake-related building damage.
As part of the Wasatch Fault Zone, the region has a complex seismic history, with at least 24 large earthquakes occurring in the urbanized parts of the zone over the past 7000 years. Along with previous excavation, borehole and other geophysical studies, the new research also supports the possibility of through-going ruptures ...
2021-06-03
At the upcoming Conference of the Parties (COP26) in November, ample discussion is likely to focus on how the world is not on track to meet the Paris Agreement's goals of stopping warming at well below 2°C. According to a new University of California San Diego article published in Nature Energy, world diplomats will, however, find encouraging signs in emerging clean energy technology "niches"--countries, states or corporations--that are pioneering decarbonization.
"In certain areas, adoption rates for solar and wind turbines, as well as electric vehicles are very high and increasing every year," write the authors of the opinion piece Ryan Hanna, assistant research scientist at UC San Diego's Center ...
2021-06-03
TAMPA, Fla. -- There are several new treatment options available for patients with advanced melanoma. While these therapies have greatly improved the prognosis for patients, each person can respond to the treatments differently. Treatment of melanomas that have spread to the central nervous system is especially challenging. In a new article published in Clinical Cancer Research, Moffitt Cancer Center researchers reveal how different therapies impact the surrounding immune environment of metastatic melanoma tumors according to location and identify a rare population of immune cells that is associated with improved overall survival.
Different types of cancer tend to spread to specific sites throughout the body. Common sites of melanoma ...
2021-06-03
The pros make it look easy, but making a movie with a drone can be anything but.
First, it takes skill to fly the often expensive pieces of equipment smoothly and without crashing. And once you've mastered flying, there are camera angles, panning speeds, trajectories and flight paths to plan.
With all the sensors and processing power onboard a drone and embedded in its camera, there must be a better way to capture the perfect shot.
"Sometimes you just want to tell the drone to make an exciting video," said Rogerio Bonatti, a Ph.D. candidate in Carnegie Mellon University's Robotics Institute.
Bonatti was part ...
2021-06-03
North Carolina State University researchers have developed a computer simulation tool to predict when and where pests and diseases will attack crops or forests, and also test when to apply pesticides or other management strategies to contain them.
"It's like having a bunch of different Earths to experiment on to test how something will work before spending the time, money and effort to do it," said the study's lead author Chris Jones, research scholar at North Carolina State University's Center for Geospatial Analytics.
In the journal Frontiers in Ecology and the Environment, researchers reported on their efforts to develop and test ...
2021-06-03
KINGSTON, R.I. - June 3, 2021 - Scientists from the University of Rhode Island have taken the first steps toward understanding the function of microbes that live on and in Eastern oysters, which may have implications for oyster health and the management of oyster reefs and aquaculture facilities.
"Marine invertebrates like oysters, corals and sponges have a very active microbiome that could potentially play a role in the function of the organism itself," said Ying Zhang, URI associate professor of cell and molecular biology. "We know very little about whether there are resident microbes in oysters, and if there are, what their function may be or how they may help or bring harm to the oyster."
Zhang and doctoral student Zachary Pimentel extracted the DNA of microbes living in ...
2021-06-03
ANN ARBOR, Mich. -- A different type of surge may be on the way more than a year into the pandemic - a baby surge.
The COVID-19 shutdown initially seemed to hit pause on pregnancy and birth rates, new research from one major hospital system suggests, but that trend is quickly reversing.
"Birth rates declined early on in the pandemic, but we expect a dramatic rebound soon," says lead author Molly Stout, M.D., MSci, maternal fetal medicine director at Michigan Medicine Von Voigtlander Women's Hospital.
"We're already seeing signs of a summer baby surge."
While infectious ...
2021-06-03
UPTON, NY--A team of researchers led by chemists at the U.S. Department of Energy's (DOE) Brookhaven National Laboratory has studied an elusive property in cathode materials, called a valence gradient, to understand its effect on battery performance. The findings, published in Nature Communications, demonstrated that the valence gradient can serve as a new approach for stabilizing the structure of high-nickel-content cathodes against degradation and safety issues.
High-nickel-content cathodes have captured the attention of scientists for their high capacity, a chemical property that could power electric vehicles over much longer distances than current batteries support. Unfortunately, the high nickel content also causes these cathode materials to degrade more quickly, creating cracks ...
2021-06-03
The South Pole and the rest of East Antarctica is cold now and was even more frigid during the most recent ice age around 20,000 years ago -- but not quite as cold as previously believed.
University of Washington glaciologists are co-authors on two papers that analyzed Antarctic ice cores to understand the continent's air temperatures during the most recent glacial period. The results help understand how the region behaves during a major climate transition.
In one paper, an international team of researchers, including three at the UW, analyzed seven ice cores from across West and East Antarctica. The results published June 3 in Science show warmer ice age temperatures in the eastern part of the continent.
The team ...
2021-06-03
Scientists have gained the best view yet of the brightest explosions in the universe: A specialised observatory in Namibia has recorded the most energetic radiation and longest gamma-ray afterglow of a so-called gamma-ray burst (GRB) to date. The observations with the High Energy Stereoscopic System (H.E.S.S.) challenge the established idea of how gamma-rays are produced in these colossal stellar explosions which are the birth cries of black holes, as the international team reports in the journal Science.
"Gamma-ray bursts are bright X-ray and gamma-ray flashes observed in the sky, emitted by distant extragalactic sources," explains DESY scientist Sylvia Zhu, one of the authors of the ...
LAST 30 PRESS RELEASES:
[Press-News.org] Immunotherapy after bladder cancer surgery may reduce recurrence, study shows
New research found that using nivolumab reduced bladder cancer recurrence after surgery compared to patients who received placebo
